The missing link in mHealth. How do we break down the glass wall between consumers/patients and the medical professional community.
A presentation at HealthCamp San Diego by Mark Scrimshire and Robert Furberg.
"The value of a European approach to mHealth in cancer Unleashing the mHealth...3GDR
The value of a European approach to mHealth in cancer
Unleashing the mHealth potential for cancer patients
Pēteris Zilgalvis
Head of Unit Health and Wellbeing
DG Communications Networks, Content and Technology
Peteris Zilgalvis, Head of the Health & Wellbeing Unit, European Commission, DG
-----
This was presented at the "Unleashing the mHealth potential for cancer patients" event held on Wednesday 25th May 2016 (16:30-18:30pm) in the European Parliament.
#mHealthCancer
"mHealth and eHealth are becoming realities in Europe: this is demonstrated by the growing size of mHealth apps’ market, by the raising investments in eHealth infrastructures and by the fast adoption, at various degrees, of mHealth applications by patients.
The burden of cancer is also raising: more than 10 million EU citizens are affected by cancer, incidence and prevalence are growing, and the socio-economic impact of cancer heavily burdens both healthcare systems and cancer patients.
The recent political agreement on the text the General Data Protection Regulation and the production of the Privacy Code of Conduct mHealth apps further stir the debate regarding the use of new mHealth technologies within cancer care pathways.
Are cancer patients enjoying the benefits of mHealth?
In which field can cancer patients profit the most from mHealth apps?
Is the regulatory framework supporting the development of useful and safe mHealth apps for cancer patients?
Are there other structural obstacles to the full integration of mHealth apps in the cancer patients’ journey?"
The event will be hosted by MEP Cristian-Silviu Busoi (EPP, Romania), one of ECPC closest champions within the European Parliament and a knowledgeable supporter of the development of eHealth/mHealth in Europe.
The event was followed by a cocktail reception.
Join the discussion on Twitter using #mHealthCancer The event is part of the initiatives for the
2016 European Week Against Cancer #EWAC2016
More information can be found on the European Cancer Patient Coalition's website:
http://www.ecpc.org/pressroom/events/icalrepeat.detail/2016/04/26/61/-/-
This slide deck is comprised of lectures delivered at Nova Southeastern University Colleges of Medicine (MI) and Pharmacy (PHA) in the following courses:
MI 6410 Consumer Health Informatics and Web 2.0 in Healthcare
PHA 5203 Consumer Health Informatics and Web 2.0 in Healthcare
"The value of a European approach to mHealth in cancer Unleashing the mHealth...3GDR
The value of a European approach to mHealth in cancer
Unleashing the mHealth potential for cancer patients
Pēteris Zilgalvis
Head of Unit Health and Wellbeing
DG Communications Networks, Content and Technology
Peteris Zilgalvis, Head of the Health & Wellbeing Unit, European Commission, DG
-----
This was presented at the "Unleashing the mHealth potential for cancer patients" event held on Wednesday 25th May 2016 (16:30-18:30pm) in the European Parliament.
#mHealthCancer
"mHealth and eHealth are becoming realities in Europe: this is demonstrated by the growing size of mHealth apps’ market, by the raising investments in eHealth infrastructures and by the fast adoption, at various degrees, of mHealth applications by patients.
The burden of cancer is also raising: more than 10 million EU citizens are affected by cancer, incidence and prevalence are growing, and the socio-economic impact of cancer heavily burdens both healthcare systems and cancer patients.
The recent political agreement on the text the General Data Protection Regulation and the production of the Privacy Code of Conduct mHealth apps further stir the debate regarding the use of new mHealth technologies within cancer care pathways.
Are cancer patients enjoying the benefits of mHealth?
In which field can cancer patients profit the most from mHealth apps?
Is the regulatory framework supporting the development of useful and safe mHealth apps for cancer patients?
Are there other structural obstacles to the full integration of mHealth apps in the cancer patients’ journey?"
The event will be hosted by MEP Cristian-Silviu Busoi (EPP, Romania), one of ECPC closest champions within the European Parliament and a knowledgeable supporter of the development of eHealth/mHealth in Europe.
The event was followed by a cocktail reception.
Join the discussion on Twitter using #mHealthCancer The event is part of the initiatives for the
2016 European Week Against Cancer #EWAC2016
More information can be found on the European Cancer Patient Coalition's website:
http://www.ecpc.org/pressroom/events/icalrepeat.detail/2016/04/26/61/-/-
This slide deck is comprised of lectures delivered at Nova Southeastern University Colleges of Medicine (MI) and Pharmacy (PHA) in the following courses:
MI 6410 Consumer Health Informatics and Web 2.0 in Healthcare
PHA 5203 Consumer Health Informatics and Web 2.0 in Healthcare
abhealth.us working with Videntity.com and NewWave.io have created ShareMyHealth and VerifyMyIdentity to enable Medicaid Beneficiaries to share their health data from the local Health Information Exchange (HIE) using FHIR and #BlueButton 2.0 style sharing. Everything is open source and built using standards (OAuth2.0, OpenID Connect and FHIR) and available from GitHub.com/transparenthealth
Blue Button 2.0 at ONC Annual Meeting - API 101 and ONC FHIR WorkshopMark Scrimshire
An overview of the Blue Button 2.0 API. This was featured at the ONC FHIR Workshop and the API 101 Session at the ONC Annual Meeting held in Washington DC in November 2018.
CMS Blue Button API - Developer Preview from Health 2.0 #h20devday, 2017Mark Scrimshire
This is the CMS Blue Button API Developer Preview presentation from the Health 2.0 Conference in Santa Clara, October 1st, 2017. The presentation was part of the Health 2.0 Dev Day Conference. The Blue Button API uses Internet standards such as OAuth2.0 and HL7 FHIR to make Medicare Claims data available to Beneficiaries so they can share that information with application, services and research programs they trust.
POET Application Verification for Consumer Health AppsMark Scrimshire
Addressing the Consumer Right of Access for the emerging world of Health APIs. POET works with OAuth2.0 to address this challenge in a scalable way. This presentation was given to the Security work group at the HL7 Workgroup meeting in San Diego, September 2017.
BlueButton on FHIR at HIMSS'17 HL7 API SymposiumMark Scrimshire
Presentation by Mark Scrimshire (@ekivemark) to the API Symposium at HIMSS'17. The presentation covered progress with building a FHIR-enabled API for Medicare beneficiaries.
An update on the progress in developing the CMS BlueButton on FHIR API to enable beneficiaries to share their data with applications, services and research programs they trust. . The api is based on the HL7 FHIR Specification. This references the Open source software provided by the Non-Profit Transparent Health foundation. Check out GitHub.com/transparenthealth.
Presenting an update on building BlueButton on FHIR at CMS to enable beneficiaries to point their data at applications, services or research programs they trust using a REST API and HL7 FHIR structured data formats.
Presented to CinderBlocks3 in Grantsville, MD on May 20th, 2016.
Aneesh Chopra - HealthCa.mp/dev Keynote. 2016: the Year to participate in the...Mark Scrimshire
On Saturday May7th, Aneesh Chopra gave a Keynote Address at HealthCa.mp/dev. This is the year to engage in the FHIR API and the FHIR Community to push HealthCare interoperability forward.
Presentation given to NORC University of Chicago Innovation Day. Talking about Entrepreneurship, HHS IDEA Lab Entrepreneur-In-Residence program, Medyear, Cloud Innovation, BlueButton and Blue Button on HIR ,
CMS BlueButton On FHIR for Researchers - Presentation to NIH and PCORI Resear...Mark Scrimshire
This is a presentation given to researchers from PCORI and NIH (Precision Medicine Initiative) about the potential benefits to researchers that comes from letting CMS Medicare Beneficiaries share their Claims information with a research study using the Proposed CMS BlueButton data formats built on the HL7 Fast Health Interoperability Resources Specification.
BlueButton On FHIR Presentation to Attachments Work Group at HL7 Meeting Jan ...Mark Scrimshire
An overview of the CMS BlueButton On FHIR initiative and how it builds on work done by the HL7 Financial Management Work Group in defining the ExplanationOfBenefit Resource for inclusion in the DSTU2.1 release of the FHIR Specification and covering the proposed Pre-Oauth Entity Trust (POET) API that will be available as a prototype at the April 1-2 HealthDataPalooza FHIR Code-a-thon. (http://healthca.mp/onfhir)
An Overview of the development of a BlueButton Data API for Medicare Beneficiaries that is being led by Mark Scrimshire, Entrepreneur-in-Residence at CMS. The objective is to build a Developer-Friendly, Standards-Based REST API that will enable Medicare Beneficiaries to connect their data with the Applications, Services and Research Programs that they trust.
This session was held on October 14th, 2015 and represents the personal views of the EIR and is not the official voice of HHS or CMS. The information is being shared to encourage partnerships in the development of FHIR to benefit patients/beneficiaries/consumers.
A Baptism of FHIR - The Layman's intro to HL7 FHIRMark Scrimshire
As I work on #BlueButton on #FHIR I find people struggling to understand how FHIR works. I am still learning myself. This was a short introductory session I gave to colleagues at CMS about the underlying mechanics of FHIR and how it can benefit Healthcare interoperability.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
abhealth.us working with Videntity.com and NewWave.io have created ShareMyHealth and VerifyMyIdentity to enable Medicaid Beneficiaries to share their health data from the local Health Information Exchange (HIE) using FHIR and #BlueButton 2.0 style sharing. Everything is open source and built using standards (OAuth2.0, OpenID Connect and FHIR) and available from GitHub.com/transparenthealth
Blue Button 2.0 at ONC Annual Meeting - API 101 and ONC FHIR WorkshopMark Scrimshire
An overview of the Blue Button 2.0 API. This was featured at the ONC FHIR Workshop and the API 101 Session at the ONC Annual Meeting held in Washington DC in November 2018.
CMS Blue Button API - Developer Preview from Health 2.0 #h20devday, 2017Mark Scrimshire
This is the CMS Blue Button API Developer Preview presentation from the Health 2.0 Conference in Santa Clara, October 1st, 2017. The presentation was part of the Health 2.0 Dev Day Conference. The Blue Button API uses Internet standards such as OAuth2.0 and HL7 FHIR to make Medicare Claims data available to Beneficiaries so they can share that information with application, services and research programs they trust.
POET Application Verification for Consumer Health AppsMark Scrimshire
Addressing the Consumer Right of Access for the emerging world of Health APIs. POET works with OAuth2.0 to address this challenge in a scalable way. This presentation was given to the Security work group at the HL7 Workgroup meeting in San Diego, September 2017.
BlueButton on FHIR at HIMSS'17 HL7 API SymposiumMark Scrimshire
Presentation by Mark Scrimshire (@ekivemark) to the API Symposium at HIMSS'17. The presentation covered progress with building a FHIR-enabled API for Medicare beneficiaries.
An update on the progress in developing the CMS BlueButton on FHIR API to enable beneficiaries to share their data with applications, services and research programs they trust. . The api is based on the HL7 FHIR Specification. This references the Open source software provided by the Non-Profit Transparent Health foundation. Check out GitHub.com/transparenthealth.
Presenting an update on building BlueButton on FHIR at CMS to enable beneficiaries to point their data at applications, services or research programs they trust using a REST API and HL7 FHIR structured data formats.
Presented to CinderBlocks3 in Grantsville, MD on May 20th, 2016.
Aneesh Chopra - HealthCa.mp/dev Keynote. 2016: the Year to participate in the...Mark Scrimshire
On Saturday May7th, Aneesh Chopra gave a Keynote Address at HealthCa.mp/dev. This is the year to engage in the FHIR API and the FHIR Community to push HealthCare interoperability forward.
Presentation given to NORC University of Chicago Innovation Day. Talking about Entrepreneurship, HHS IDEA Lab Entrepreneur-In-Residence program, Medyear, Cloud Innovation, BlueButton and Blue Button on HIR ,
CMS BlueButton On FHIR for Researchers - Presentation to NIH and PCORI Resear...Mark Scrimshire
This is a presentation given to researchers from PCORI and NIH (Precision Medicine Initiative) about the potential benefits to researchers that comes from letting CMS Medicare Beneficiaries share their Claims information with a research study using the Proposed CMS BlueButton data formats built on the HL7 Fast Health Interoperability Resources Specification.
BlueButton On FHIR Presentation to Attachments Work Group at HL7 Meeting Jan ...Mark Scrimshire
An overview of the CMS BlueButton On FHIR initiative and how it builds on work done by the HL7 Financial Management Work Group in defining the ExplanationOfBenefit Resource for inclusion in the DSTU2.1 release of the FHIR Specification and covering the proposed Pre-Oauth Entity Trust (POET) API that will be available as a prototype at the April 1-2 HealthDataPalooza FHIR Code-a-thon. (http://healthca.mp/onfhir)
An Overview of the development of a BlueButton Data API for Medicare Beneficiaries that is being led by Mark Scrimshire, Entrepreneur-in-Residence at CMS. The objective is to build a Developer-Friendly, Standards-Based REST API that will enable Medicare Beneficiaries to connect their data with the Applications, Services and Research Programs that they trust.
This session was held on October 14th, 2015 and represents the personal views of the EIR and is not the official voice of HHS or CMS. The information is being shared to encourage partnerships in the development of FHIR to benefit patients/beneficiaries/consumers.
A Baptism of FHIR - The Layman's intro to HL7 FHIRMark Scrimshire
As I work on #BlueButton on #FHIR I find people struggling to understand how FHIR works. I am still learning myself. This was a short introductory session I gave to colleagues at CMS about the underlying mechanics of FHIR and how it can benefit Healthcare interoperability.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
16. @ekivemark @MedicFurby
Reputation = Positive Feedback *
Negative Feedback*
* Feedback adjusted by Trust rating
of those providing feedback
http://healthca.mp #HCSD10
17. @ekivemark @MedicFurby
Conversation fire starters
Robert Furberg, MBA
Research Programmer
http://healthca.mp #HCSD10
18. @ekivemark @MedicFurby
Conversation fire starters
Robert Furberg, MBA
Research Programmer
mscrimshire@gmail.com medicfurby@gmail.com
http://healthca.mp #HCSD10